An Exploration

The U.S. Healthcare
Stack

How a small number of corporations came to control the insurance, the pharmacy benefits, the pharmacies, and increasingly, the care itself.

This is a map of vertical integration. It shows how the same companies that decide what your insurance covers also manage your prescriptions, fill them, and now want to be your doctor too.

American healthcare is not merely expensive. It is increasingly concentrated.

Over the past two decades, a small number of corporations have quietly assembled control across multiple layers of the healthcare system. The same company that provides your health insurance may also manage your pharmacy benefits, operate the pharmacy that fills your prescriptions, and run the clinic where you see a doctor.

This is not an accident. It is a business strategy called vertical integration. The theory is that owning multiple parts of the healthcare supply chain creates efficiencies. The reality is more complicated.

“When the same company can touch the plan, the formulary, the pharmacy, the data, and increasingly the care itself, control compounds.”

Integration creates leverage. A company that owns both a pharmacy benefit manager and a pharmacy can steer prescriptions to its own counters. A company that owns both an insurer and a network of doctors can direct patients to its own clinics. A company with visibility into claims data, prescriptions, and medical records can optimize for its own financial benefit in ways that are difficult for patients, employers, or regulators to see.

The map below is not just about scale. It is about structural power. It shows how ten corporations have positioned themselves across insurance, pharmacy benefits, retail pharmacy, specialty pharmacy, care delivery, home health, distribution, diagnostics, and health technology.

Each layer represents an opportunity to extract margin. Each connection represents influence over how care is financed, approved, routed, and delivered.

The Scale
$0.0T
18.0% of U.S. GDP

U.S. national health expenditures reached $5.3 trillion in 2024. The conglomerates mapped here sit at the center of this system—not as providers of care, but as the intermediaries who decide what gets covered, what it costs, and where patients can go.

The History

How the Stack Was Built

The current healthcare landscape did not appear all at once. It was assembled in layers, through years of strategic acquisitions and corporate combinations.

First, the rails were built. PBMs consolidated. Retail pharmacies expanded. Distribution companies moved into specialty care. Then, in a more visible wave, insurers merged with PBMs and began acquiring the care itself.

What follows is the story of how a fragmented industry became a corporate system.

Era I|2006 - 2015

Foundations of Consolidation

The Rails Were Built

Before the headline-grabbing mega-mergers of the late 2010s, the groundwork was being laid. PBMs consolidated. Retail pharmacies expanded into care. Distributors moved deeper into provider networks. These were the rails upon which later integration would run.

2006

CVS acquires MinuteClinic

An early move into care delivery inside the retail pharmacy footprint. The pharmacy counter becomes a site of clinical care.

Care DeliveryRetail Pharmacy
2007

CVS acquires Caremark

A major stack-building moment. Retail pharmacy combines with pharmacy benefit management. One company now touches both the dispensing and the formulary.

PBMRetail Pharmacy
2010

McKesson acquires US Oncology

Distribution moves into specialty provider networks. The line between logistics and care begins to blur.

DistributionSpecialty
2012

Express Scripts acquires Medco

A major consolidation in the PBM layer. Two of the largest pharmacy benefit managers become one.

PBM
2015

CVS expands through Omnicare, Coram, and Target pharmacies

A rapid expansion across specialty infusion, long-term care pharmacy, and retail footprint. The stack grows wider.

Specialty PharmacyRetail PharmacyCare Delivery
2015

OptumRx acquires Catamaran

UnitedHealth strengthens its PBM position. The insurer now has a more robust pharmacy benefits arm.

PBM
The Acceleration

The groundwork had been laid. The rails were in place. Now the strategy would become unmistakable: own every layer the patient touches.

Era II|2018 - 2023

Full-Stack Expansion

The Strategy Becomes Visible

The quiet assembly gives way to unmistakable integration. Insurers combine with PBMs. Care delivery becomes a corporate priority. Home health enters the portfolio. By the early 2020s, the strategy is no longer subtle: own every layer the patient touches.

2018

CVS Health completes acquisition of Aetna

Pharmacy, PBM, and insurer under one roof. A defining moment in healthcare consolidation. The full stack begins to crystallize.

InsurancePBMRetail Pharmacy
2018

Cigna completes combination with Express Scripts

Another insurer absorbs a PBM. The pattern becomes unmistakable. Vertical integration is now the dominant strategy.

InsurancePBM
2019

Optum completes acquisition of DaVita Medical Group

UnitedHealth moves deeper into direct care delivery. The insurer now employs physicians and operates clinics.

Care DeliveryInsurance
2021

Humana acquires remaining stake in Kindred at Home

A significant expansion into home health. Care moves beyond the clinic and into the living room.

Home HealthInsurance
2022

Optum completes combination with Change Healthcare

The data layer is claimed. Claims, payments, and infrastructure now flow through the same corporation that insures and treats patients.

Data & AnalyticsClaimsInsurance
2023

CVS completes acquisition of Signify Health

Home-based care and provider enablement enter the CVS portfolio. The reach extends into where patients live.

Home HealthCare Delivery
2023

CVS completes acquisition of Oak Street Health

Primary care at scale. CVS now operates value-based clinics focused on Medicare patients. The stack is nearly complete.

Primary CareCare Delivery

This is how the stack was built. Layer by layer. Acquisition by acquisition. Now, see what the finished system looks like.

Continue
The Evidence
0
Combined Revenue
Annual revenue of the ten conglomerates mapped below
0
PBM Market Share
Controlled by three companies: CVS Caremark, Express Scripts, OptumRx
0
Conglomerates
Spanning insurance, pharmacy, care delivery, and more
0
Sectors
Layers of the healthcare system where these companies operate

Revenue figures from official FY2025 earnings reports. PBM market share from industry analysis.

Financial Overview

Combined Annual Revenue

These ten conglomerates generate over $2 trillion in annual revenue, representing a significant portion of U.S. healthcare spending. Click the chart to explore each conglomerate and their subsidiaries.

Total Revenue
$2257.8B
Combined FY2025

Revenue figures from official FY2025 earnings reports. Click a company to explore its subsidiaries.

The Map

See how much one company controls

Hover over a conglomerate to reveal its reach across the healthcare system. Each highlighted cell represents a sector where that company has positioned itself to influence cost, access, or care delivery.

Hover over a conglomerate to highlight its presence. Click for details.

What This Means

How vertical integration compounds control

Owning multiple layers of the healthcare system is not just about scale. It creates structural power that shapes how care is financed, approved, routed, and delivered.

Insurer + PBM

When an insurer owns the pharmacy benefit manager, it controls both what drugs are covered and how much pharmacies get paid for dispensing them.

Insurance+PBM
The Implication

The company profits from both premium collection and PBM fees, with limited external oversight of formulary decisions.

PBM + Pharmacy

When a PBM owns pharmacies, it can steer prescriptions to its own stores while setting reimbursement rates for competitors.

PBM+Retail Pharmacy+Specialty Pharmacy
The Implication

Independent pharmacies face rates set by a direct competitor. Mail-order prescriptions are often routed to captive pharmacies.

Insurer + Care Delivery

When an insurer owns clinics and employs physicians, it can direct patients to its own providers and influence treatment decisions.

Insurance+Care Delivery
The Implication

The company that pays for care also delivers it. Cost containment and clinical judgment can become difficult to separate.

Full Stack Control

Some conglomerates now span insurance, PBM, pharmacy, and care delivery all at once, touching nearly every step of a patient's healthcare journey.

Insurance+PBM+Pharmacy+Care Delivery+Data
The Implication

A single corporation can approve your coverage, manage your prescriptions, fill them, and increasingly be your doctor too.

“Integration is not inherently bad. But when the same company that approves your treatment also profits from steering it, the patient is not the only one being optimized for.”
The Consequences

What concentration means for patients

This system was not designed with affordability as its primary goal. The structure itself shapes what is possible.

Rising Costs

Healthcare spending continues to grow faster than inflation, with more margin captured at each layer of the system. Integration was supposed to create efficiencies. Prices suggest otherwise.

Opaque Pricing

When a company operates the PBM, the pharmacy, and the insurer, there are internal transfers that patients, employers, and regulators cannot easily see. Rebates, spreads, and fees flow between related entities.

Limited Leverage

Patients have little negotiating power in a system where choices are increasingly constrained. Network restrictions, formulary decisions, and prior authorization requirements are set by companies that profit from the friction.

Captured Margins

Each layer of the stack represents an opportunity to extract value. When a single company controls multiple layers, it can optimize margin capture across the entire patient journey.

Complexity as Feature

The system & complexity is not a bug. It benefits institutions that can navigate it while leaving patients, employers, and small providers struggling to understand where money actually goes.

Misaligned Incentives

When the same company profits from covering care, managing benefits, filling prescriptions, and delivering treatment, whose interests are being optimized? The answer is not always the patient.

“The question is not whether these companies are efficient. It is whether the system they have built serves the people who depend on it or the shareholders who own it.”

The issue is not simply that American healthcare is expensive. It is that more of it is being controlled by fewer companies. And those companies are increasingly positioned to profit from multiple points in the same patient journey.

This visualization is not an argument against all integration or consolidation. It is an attempt to make visible the structure of a system that most people navigate without understanding who controls what. Transparency is the first step toward accountability.